

Descriptive study of Extragastrintestinal Manifestations of Ulcerative Colitis and their relation to disease activity in 100 Iraqi patients

Khalid A. Al-Khazraji* CAMB, MRCP (Glas.), FRCP (Glas.), FACP

Summary:

Background: Ulcerative colitis is a chronic inflammatory bowel disease (IBD); its extragastrintestinal manifestations vary from one country to another. This study identifies the prevalence of the extragastrintestinal manifestations in a sample of Iraqi patients with ulcerative colitis and their relation to disease activity.

Patients and Methods: A descriptive study was conducted on 100 patients with established diagnosis of ulcerative colitis, who attended Baghdad Teaching hospital and Gastroenterology center in Baghdad during the period from May 2009 to January 2010. A direct interview and thorough clinical examination were done to determine the history of the disease, its severity and the presence or absence of the extraintestinal manifestations.

Result: The Extragastrintestinal manifestations were observed in 17 patients (17%). The most common EGIMs were the peripheral arthritis and mouth ulcer. The EGIMs were more common in patients with severe disease.

Conclusion: The EGIMs of ulcerative are less common in Iraqi patients than in patients from western countries, but their relation with disease activity was relatively similar.

Keywords: ulcerative colitis. extragastrintestinal manifestatio

*Fac Med Baghdad
2011; Vol. 53, No. 1
Received Sept. 2010
Accepted Jan. 2011*

Introduction

Ulcerative colitis (UC) is a chronic inflammatory condition of unknown aetiology, mainly involving the large bowel, characterized by diffuse mucosal and submucosal inflammation limited to the colon and rectum. It extends proximally in a symmetrical, circumferential pattern to involve parts or all of the large intestine. The dominant symptom in ulcerative colitis is diarrhea, which is usually, but not always, associated with blood in the stool. The diarrhea is often associated with rectal urgency and tenesmus. The clinical course is characterized by exacerbations and remissions that may occur spontaneously or in response to medical management. (1), the incidence and prevalence of ulcerative colitis vary with geographic location; the highest rates occur in white populations in northern Europe & North America, where the incidence is about 5 per 100,000 and the prevalence is approximately 50 per 100,000. (2)

Extraintestinal Manifestation : Some of these manifestations are related to the activity of the colitis other are not (3) The reported frequency of EGIMs in patients with IBD varies from 6%-47%, but generally up to one-third of IBD patients have at least one extragastrintestinal-manifestation (4,7) , **Related to activity of colitis:** Peripheral arthropathy , Erythema nodosum , Episcleritis, anterior uveitis conjunctivitis , Aphthous ulceration of the mouth , Fatty liver , Pyoderma gangrenosum , **Unrelated to activity of colitis:** Sacroiliitis , Ankylosing spondylitis , Primary sclerosing cholangitis , Metabolic bone disorders , Thromboembolic disorders , Pericarditis , Acute febrile neutrophilic dermatosis Sweets syndrome , Amyloidosis.

Patients and Methods:

This descriptive study was conducted on 100 patients who attended Baghdad Teaching Hospital and Gastroenterology center in Baghdad, during the periods from May 2009 to January 2010. All eligible patients had an established diagnosis of ulcerative colitis based on clinical, endoscopic and histopathological findings.

Any patient who had in addition a diagnosis of other autoimmune disease (e.g. rheumatoid arthritis, SLE) was excluded from the study because they may have

clinical features that simulate extraintestinal manifestations of ulcerative colitis.

A questionnaire was designed to evaluate the patients by direct interview including patient name, age, gender, date of diagnosis, and history of smoking.

The other parts of the questionnaire included assessment of disease activity and reporting any extragastrintestinal manifestations may the patient had.

Table -1- Mayo Scoring system for assessment of ulcerative colitis severity. ⁽⁶⁾

1. Stool frequency
 - = Normal no. of stool
 - = 1 to 2 stools more than the normal
 - = 3 to 4 stools more than the normal
 - = 5 or more stools more than the normal
 2. Rectal bleeding
 - = No bleeding seen
 - = streaks of blood in the stool less than half the time
 - = Obvious blood with the stool most of the time
 - = Blood alone pass
 3. Finding on endoscopy
 - = Normal
 - = mild disease (erythema, decrease vascular pattern , mild friability)
 - = moderate disease.(marked erythema, lack of vascular pattern, friability, erosions)
 - = Severe disease (spontaneous bleeding, ulcerations)
 4. Physician's global assessment£
 - = Normal
 - = Mild disease
 - = Moderate disease
 - = severe disease
- £ Physician's global assessment acknowledges the three other criteria, the patient daily recollection of abdominal discomfort and general sense of well being, and other observations, such as physical findings and patient performance state.

Results:

One hundreds (100) patients were included in the study, 57 (57%) were males and 43 (43%) were females, the youngest patient was 17 years old and the oldest was 83 years, the mean age of the patients was (46.2).the duration of the disease was ranging from less 1 years to 20 years. Table (2) shows the

*Dept. of medicine, College of Medicine University of Baghdad.

distribution of Ulcerative colitis in the studied patients according to age , gender , and the duration of the disease.

Table 2: Distribution of ulcerative colitis according to gender, age, and disease duration.

1- Gender	Number	%
Male	57	57%
Female	43	43%
2- Age group (years)		
<20	3	3%
20-40	34	34%
40-60	45	45%
>60	18	18%
3- Disease duration(years)		
<1	14	14%
1-5	48	48%
>5	38	38%
Total	100	100%

Extragastrintestinal manifestations were verified in 17 patients (17%), 9 (52.9%) of them were males and 8 (47.1%) were females, table (3) shows distribution of EGIMs among the studied patients .

Table -3- Distribution of EIMs among patients.

Extraintestinal manifestation	Male n(%)	Female n(%)	Total n(%)
Oral ulcer	1(5.88%)	1(5.88%)	2(11.76%)
Peripheral arthritis	1(5.88%)	1(5.88%)	2(11.76%)
Ankylosing spondylitis	1(5.88%)	0(0%)	1(5.88%)
Sacroiliitis	0(0%)	1(5.88%)	1(5.88%)
Deep venous thrombosis	1(5.88%)	0(0%)	1(5.88%)
Oral ulcer + Periph. arthritis	1(5.88%)	1(5.88%)	2(11.76%)
Oral ulcer + conjunctivitis	1(5.88%)	0(0%)	1(5.88%)
Oral ulcer + Anterior uveitis	0(0%)	1(5.88%)	1(5.88%)
Periph.arthritis + Ankylosing spondylitis	1(5.88%)	1(5.88%)	2(11.76%)
A.spondylitis + Sacroiliitis	0(0%)	1(5.88%)	1(5.88%)
Oral ulcer + Periph.arthritis + Erythema nodosum	1(5.88%)	0(0%)	1(5.88%)
Oral ulcer+Periph.arthritis + Erythema nodosum +Conjunctivitis	0(0%)	1(5.88%)	1(5.88%)
Oral ulcer + Periph.arthritis + Ankylosing spondylitis	1(5.88%)	0(0%)	1(5.88%)
Total	9 (52.9%)	8 (47.1%)	17 (100%)

Extragastrintestinal manifestations were more common in patients with age less than 40 years than in those with age more than 40 years and this difference stated as significant (**p-value** =0.04). The mean age of males with EGIM was (40.1) years and of females was (40.3) years and the difference was statistically insignificant (**p-value**=0.9). Which means that there was no age predominance of EIMs in neither gender compared to the other, Table (4) shows the distribution of extraintestinal manifestations according to age groups and gender.

Table- 4 - Distribution of patients with and without EGIMs according to age groups and gender

All Patients	Males			Females		
	EIM	No EIM	Total	EIM	No EIM	Total
Age groups						
<20	1	2	3	1	1	2
20-40	9	25	34	4	14	18
40-60	5	40	45	3	24	27
>60	2	16	18	1	9	10
Total	17	83	100	9	48	57
Mean ageing	40.2	47.1	46.2	40.1	46.8	46.3
-+SD	13.2	12.6	12.4	13.5	12.3	12.7
	13.4	12.4	12.5			

The presence of Extragastrintestinal manifestations were more common among females (8 of 43=18.6%) than in males (9 Of 57= 15.7%) but the difference was statistically insignificant (p-value=0.45). table (5).

The extraintestinal manifestations were more common in patients with disease duration more than 5 years than in those with less than 5 years duration and the association of extragastrintestinal manifestations with disease duration was statistically significant (p-value=0.047). table (6).

Table- 5 - Distribution of patients with EIM according to disease.

Disease duration	With EIM	Without EIM	Total	P-value
< 1 year	1(7.1%)	13(92.9%)	14(100%)	0.047
1-5 years	6(12.5%)	42(87.5%)	48(100%)	
> 5 years	10(26.3%)	28(73.7%)	38(100%)	

Table (6) shows the prevalence of Extragastrintestinal manifestations among the studied patients , where the peripheral arthritis and oral ulcer were the most common Extragastrintestinal

manifestations ,while episcleritis and pyoderma gangrenosum were not verified in any patient.

Table -6- The prevalence of extraintestinal manifestations among all patients

Extraintestinal manifestation	patient with EIM	% of total pt.
Mouth ulcer	9	9%
conjunctivitis	2	2%
episcleritis	0	0%
Anterior uveitis	1	1%
Peripheral arthritis	9	9%
Ankylosing spondylitis	4	4%
Sacroiliitis	3	3%
Erythema nodosum	2	2%
Pyoderma Gangrenosum	0	0%
Deep venous thrombosis	1	1%

Table (7) shows the prevalence of each Extragastrintestinal manifestation according to gender , despite the difference in the prevalence of EIM among genders, no one of these differences was statistically significant .(all the estimated P-value was > 0.05, although the number of some EIM was very low for valuable statistical analysis)

Table 7 : Distribution of EIMs according to gender

	Total	Male(% among male)	Female(% among female)	P-value
Oral Ulcer	9	5(8.7%)	4(9.3%)	0.59
Conjunctivitis	2	2(3.5%)	0(0%)	0.32
Episcleritis	0	0(0%)	0(0%)	
Anterior Uveitis	1	0(0%)	1(2.3%)	0.43
Peripheral arthritis	9	5(8.7%)	4(9.3%)	0.59
Ankylosing Spondylitis	4	2(3.5%)	2(4.6%)	0.57
Sacroiliitis	3	2(3.5%)	1(2.3%)	0.61
Erythema Nodosum	2	1(1.7%)	1(2.3%)	0.67
Pyoderma Gangrenosum	0	0(0%)	0(0%)	
DVT	1	1(1.7%)	0(0)	0.57

Table (8) Represent the patients with extraintestinal manifestation according to the severity of ulcerative colitis ,and show that the risk of having extraintestinal manifestations was significantly higher in patients with moderate to severe disease than in patients with mild and in a remission disease (p-value=0.002).

Table – 8 – Distribution of the patients with EIM according to the severity of DIA (Mayo) score

Disease severity	Total	Patients with EIM%
Remission (score <2)	22	1(4.5%)
Mild (score 3-5)	46	5(10.6%)
Moderate (score 6-10)	19	5(31.2)
Severe (score > 10)	13	6(46.1%)
Total	100	17

Table-9- Distribution of EIMs according to the severity of DAI (Mayo) score

The Extraintestinal Manifestation	Remission Score <2	Mild Score 2-5	Moderate score 6-10	Severe score>10	Total	P-value
Oral ulcer	-	1(11.1%)	3(33.3%)	5(55.6%)	9(100%)	< 0.001
Conjunctivitis	-	1(50%)	-	1(50%)	2(100%)	0.41
episcleritis	-	-	-	-	-	
Ant.Uveitis	-	-	1(100%)	-	1(100%)	0.34
Periph.arthritis	-	2(22.2%)	2(22.2%)	5(55.6%)	9(100%)	0.003
Ank.spondylitis	1(25%)	3(75%)	-	-	4(100%)	0.19
Sacroiliitis	1(33.3%)	-	2(66.7%)	-	3(100%)	0.24
Erythem.Nodosum	-	-	-	2(100%)	2(100%)	0.01
Pyo.Gangrenosum	-	-	-	-	-	
DVT	-	1(100%)	-	-	1(100%)	0.34

Two patients (11.7%), one with ankylosing spondylitis and the other with sacroiliitis had developed these EIMs before the intestinal manifestations of Ulcerative colitis became clinically evident.

Two of the studied patients were having a skin disease which diagnosed as lichen planus.

Discussion:

Ulcerative colitis is a chronic, relapsing and progressive inflammatory bowel disease of uncertain etiology thought to be triggered by genetic, environmental, and immunological factors [7].

Far from its bowel manifestation, ulcerative colitis has many extraintestinal manifestations (EIMs), and it has been reported that these EIMs affect almost any organ system in the body [8] . Due to the fact that one EIM increase the risk for developing the other EIMs [9], this study tries to focus on the most commonly and easily described EIMs. Many systems were discussed for the evaluation of the disease activity, we selected the Mayo score system due to its simplicity and its collection to a numerical score, indeed that the Food and Drug Administration (FDA) currently favors the Mayo score, or Disease Activity Index (DAI) [4], for trial design in ulcerative colitis, although it is not yet completely wedded to this.

From 100 patients who were enrolled in this study the Extragastrintestinal manifestations were verified in 17 patients (17%) although we didn't include the all EIMs of UC, this rate was lower than the prevalence of

Table (9) shows the prevalence of each extraintestinal manifestation according to the severity of ulcerative colitis as following:

Oral Ulcer: the risk of having oral ulcer is significantly higher in patients with moderate to severe disease than in patients with mild and in a remission disease (p-value =<0.001) which indicate that oral ulcer is highly related to disease activity

Peripheral arthritis: the risk of having Peripheral arthritis is significantly higher in patients with moderate to severe disease than in patients with mild and in a remission disease (p-value =0.003) which indicate that: Peripheral arthritis is highly related to disease activity Erythema Nodosum: present only in patients with severe disease, and its relation to disease activity stated as significant (P-value: 0.01) which indicate its relation to disease activity.

Sacroiliitis: was verified in 1 patient with mild disease and 2 patients with moderate disease but its relation to disease activity was statistically not significant.(P-value=0.24) i.e not related to disease activity.

Ankylosing spondylitis: was only verified in patients with mild & in a remission disease and it was not related to disease activity.(P-value=0.19)

Eye manifestations: conjunctivitis found in one patient with mild disease and one with severe disease, uveitis in one patient with moderate activity. The number was low to show the relation with disease activity.

DVT: was present in one patient with mild disease.

the same EIMs in many western countries (10, 11,) , but it was relatively consistent with many studies from the middle east (12, 13,) , also it has been reported that EIMs is less commonly observed in Arab population (14). and other studies reported that the EIMs is significantly lower in Asia and Africa(15,16).

In agreement with many studies, this study showed that the EIMs of ulcerative colitis tend to occur in younger patients (17, 18).

In this study we found that the occurrence of EIMs was significantly associated with longer disease duration which was consistent with many studies [69~71]

No much data are available that compare the rate of EIM between males and females , how ever our study was in consistence with three Other studies done in the western countries (18,19) which reported a slight female predominance . In agreement with most of references (2), and studies (15, 16, 20), our study showed that the patient with greater severity of colitis carry a higher risk for the development of EIMs. As with most other studies our study showed that the most frequent EIM is peripheral arthritis (15, 21, and 22). The rate of peripheral arthritis in this study was 9%. and despite the different ranges of the rate of peripheral arthritis mentioned in the references (2, 3), the rate in our patients was lower than what reported in western studies in which the rate was >22% [23, 24, 25¹, and consistent with one Omani study (12) in which the rate was also 9%.in accordance to many references and studies (2, 26), this study showed that

peripheral arthritis ran a course parallel to the disease activity.

Also different ranges for Ankylosing spondylitis is reported from 1% to 20% [3,28], in our study Ankylosing spondylitis was verified in 4% of the patients and as with those studies it ran a course independent to disease activity. The reported range of sacroiliitis is (10-20%) [3,28,29], while only 4 patients (4%) in our study have sacroiliitis, and in consistent with these reports, the course of sacroiliitis in our patient was not related to disease activity.

In argument with many reports [30,31]; which mentioned that oral ulcer is more commonly related to Crohn's disease, in our study the oral ulcer was found in 9 patient (9%) but in accordance to these reports it was highly related to disease activity.

The reported rates of Erythema nodosum in western area was (5-15%) [27], while the rate in this study was 2%, which was also lower than what was reported in the study of Aftab A. et al in Omani population. In consistent with most of references (8,27) Erythema nodosum was related to disease activity in our study.

Pyoderma gangrenosum reported in 2-5% of patient with IBD and it was suggested that it is more common in U.C than Crohn's disease (27), While no single case is reported in this study

The reported rate of ocular manifestations is 1-6% [32] in our study it was 3%. Studies relate them to disease activity (38), in our study it was verified in mild moderate and severe disease. It had been reported that episcleritis is the most common ocular manifestation of UC (32), while no single case is found in our study.

The rate of DVT is estimated to be 1-2% (34,35). in our study it was verified in one patient (1%), and as with those report it was unrelated to disease activity.

Two of patients (11.7%) who were enrolled in our study developed EIMs (one with Ankylosing spondylitis and the other with sacroiliitis) before the intestinal symptoms of ulcerative colitis became clinically evident, this was in consistent with many reports (19,36)

Two patients in our study had been diagnosed with Lichen planus, despite the wide spectrum of skin manifestations mentioned in many references (37,38, 39, 40) no one reported that lichen planus is a manifestation of inflammatory bowel disease, whether this manifestation is related to Ulcerative Colitis or not it need to be followed more. The pathogenesis of EIMs associated with IBD is poorly understood. Many EIMs are hypothesized to be due to immune reactions, supported by the observations that primarily immunological derangements progress to the development of IBD and that patients with EIM have an increased risk of autoimmune diseases (41)

Genetic factors also have been implicated in the pathogenesis of EIMs in IBD. Ethnic and racial differences in IBD phenotype have potential implications for diagnosis and management of IBD and its complications (42). Studies reveal associations of EIMs in IBD with major histocompatibility complex loci. For examples, patients with CD who have EIMs are more likely to have HLA-A2, HLA-DR1, and HLA-DQw5, whereas patients with UC and EIMs are more likely to have HLA-DR103, B27, and B58 phenotypes (43).

Some of above facts may explain the lower incidence of EIMs in our population, in addition it has been reported that ulcerative colitis in the Middle Eastern population is generally a less extensive disease of mild to moderate severity (44, 45).

Conclusion

Although this study didn't enroll all the extragastrintestinal manifestations of Ulcerative colitis, the studied EIMs were less common in our

locality compared to western countries. And relatively were in accordance with reports from Middle East countries

The EIMs were more common in patients with active disease.

EIMs of Ulcerative tend to occur in younger patients with longer duration of the ulcerative colitis.

There was no significant difference in the rate of EIMs between males and females.

EIMs may precede the intestinal symptoms of Ulcerative Colitis.

References

1. Kornbluth A, Sachar DB. *Ulcerative colitis practice guidelines in adults (update): American college of Gastroenterology, practice parameters committee.* *Am J Gastroenterol* 2004;99:1371.
2. Goldman, Ausiello, Arend, Armitag, Clemmons, Drazen, Griggag, La-Russo Cecil *Medicine* 2008;23:1042-46.
3. Chinyu S, Gray R, Lichtenstein, Mark F, Laurence S, Laurance J, Slesinger & Fortran's, *Gastrointestinal & Liver disease.* 2006;8;109:2499-2517
4. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. *The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.* *Am J Gastroenterol* 2001; 96:1116-1122.
5. Schroeder KW, Tremaine WJ, Ilstrup DM: *Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis.* *N Eng J Med* 1987, 317(26):1625-1629.
6. Kate S, Kane S, Higgin P, et al *Different definitions of remission for U.C result in large variation of clinical outcome score* *Gastroenterology* 2006,130(suppl2):A-482.
7. Pinsk V, Lemberg DA, Grewal K, Barker CC, Schreiber RA, Jacobson K. *Inflammatory bowel disease in the South Asian Pediatric Population of British Columbia.* *Am J Gastroenterology.* 2007; 102:1077 - 1083.
8. Bernstein CN, Blanchard JF, Rawsthorne P, et al. *The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.* *Am J Gastroenterol* 2001; 96:995-1012.
9. Das KM, Vecchi M, Sakamak S. *A shared and unique epitope(s) on human solitis, skin and biliary epithelium detected by a monoclonal antibody.* *Gastroenterology* 1990; 98: 464-469.
10. Greestein AJ, Janowitz HD, Sacher DB. *The extraintestinal complications of Crohns disease and ulcerative colitis, A study of 700 patients.* *Medicine* 1976; 55: 401-412.
11. Kocchra R, Mehta SK, Nagi B, Bhatia V, Goenka MK, Malk AK. *Extraintestinal manifestations of idiopathic ulcerative colitis.* *Indian J. Gastroenterology* 1992; 11: 45
12. Aftab Ahmed Siddiqui, Babar Bashir, Moin Ahmed Ansari, Rakhshinda Jabeen Saeed Ahmed and Masoud Bakheet Khashoob. *Extra-intestinal Manifestations of Ulcerative Colitis in Omani Population: A Study of 100 Cases.* *JLUMHS January - april 2009; vol: 08 no. 01.*
13. Loftus EV Jr. *Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences.* *Gastroenterology.* 2004; 126: 1504 -1517.
14. Hossain J, Al Faleh F Z, Al Mofleh I, Al Asha A, Laajam M, Al Rashed R. *Does ulcerative colitis exist in Saudi Arabia? Analysis of Thirty seven cases.* *Saudi Med J* 1989; 10: 360-82.
15. Sath MB, Al-Quorain A, Al-Gindan Y, Al-Hamdan A. *Chronic idiopathic ulcerative colitis Saudi Arabia: A clinicopathological study of 76 cases.* *Amm Saudi Med* 1996; 16: 637-640.

16. Pangprasobchai S, Manatsathit S, Leelakusolvang S, Sattowatthamrong Y, Boongapisit S. Ulcerative colitis in Thailand: a clinical study and long term follow-up. *J Med Assoc Thai* 2001; 84:1281-1288.
17. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel diseases. *Gastroenterology Clin North Am* 1999; 28: 491.
18. Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of EM associated with ulcerative colitis after proctocolectomy. *Dig Surg* 2001; 18: 51-55.
19. Bernstein CN, Blachard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population based study. *Am J Gastroenterology* 2001; 96:1116-1122.
20. Mosebach S, Tromm A, Wittenborg A, May B. Rheumatic complaints with Morbus Crohn and ulcerative colitis dominance of non-inflammatory factors. In: *Inflammatory Bowel Diseases. New developments and standards.* 1995; 85: 74.
21. Jojic Nj, Djurdjevic D, Milutinovic S, Jovicic S, Kekic Z, Alic M. Epidemiology of inflammatory bowel diseases in one Belgrade area. *Arch Gastroenterohepatology* 2000; 19: 3-4.
22. Bargaen JA. Complications and sequelae of chronic ulcerative colitis. *Ann Intern Med* 1929; 3: 335-352.
23. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in IBD: their articular distribution and natural history. *Gut* 1998; 42: 387-391.
24. Karoly Z, Eros N, Ujszaszy L, Nagy G. Cutaneous and mucosal manifestations of inflammatory bowel diseases. *Orv Hetil* 2000; 141:1391-1395.
25. Brynskov J, Binder U. Arthritis and the gut. *Eur J Gastroenterology Hepatology* 1999; 11: 997-999.
26. Orchard T, Wordsworth B, Jewell D. The peripheral arthropathies of inflammatory bowel disease: their articular distribution and natural history. *Gut* 1998; 42: 387-391.
27. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. *Medicine (Baltimore)* 1976; 55:401-412.
28. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol* 1996; 23:29-34.
29. Caspi RR, Stiff LR, Morawetz R, et al. Cytokine-dependent modulation of oral tolerance in a murine model of autoimmune uveitis. *Ann N Y Acad Sci* 1996; 778:315-324.
30. Ficarra G, Cicchi P, Amorosi A, et al. Oral Crohn's disease and pyostomatitis vegetans. An unusual association. *Oral Surg Oral Med Oral Pathol* 1993; 75:220-224.
31. Philpot HC, Elewski BE, Banwell JG, et al. Pyostomatitis vegetans and primary sclerosing cholangitis: markers of inflammatory bowel disease. *Gastroenterology* 1992; 103:668-674.
32. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol*; 1996; 23:29-34.
33. Orchard TR, Chua CN, Ahmed T, Cheng N, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel diseases: clinical features and the role of HLA genes. *Gastroenterology* 2002; 12: 714-718.
34. Paradis K, Bernstein ML, Adelson JW. Thrombosis as a complication of inflammatory bowel disease in children: a report of four cases. *JPediatr Gastroenterol Nutr* 1985; 4:659-662.
35. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. *Thromb Haemost* 2001; 85:430-434
36. Levine Joel B. Extraintestinal manifestations of inflammatory bowel diseases In Philadelphia, 2000; 397-409.
37. Ytting H, Vind I, Bang D, et al. Sweet's syndrome - an extraintestinal manifestation in inflammatory bowel disease. *Digestion* 2005; 72:195-200.
38. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. *Gastroenterology* 2000; 118:274-278.
39. Banet DE, McClave SA, Callen JP. Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease. *J Rheumatol* 1994; 21:1766-1768.
40. Eisner J, Kiehl P, Kapp A, et al. Erythema elevatum and diutinum in Crohn disease. *Hautarzt* 1996; 47:701-704.
41. Snook JA, de Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. *Q J Med* 1989; 72:835-840.
42. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. *Am J Gastroenterol* 2006; 101:1012-1023.
43. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. *Gastroenterology* 1997; 112:1845-1853.
44. Hossain J, Al-Faleh FZ, Al-Mofleh I, Al-Aska A, Laajam MA, Al-Rashed R. Does ulcerative colitis exist in Saudi Arabia? Analysis of thirty-seven cases. *Saudi Med J* 1989; 10:360-2.
45. Rachel M Cooney, Bryan F Warren, Douglas G Altman, Maria T Abreu and Simon PL Travis. Outcome measurement in clinical trials for Ulcerative Colitis towards standardization. *Trials* 2007, 8:17